What is Tirzepatide?
Tirzepatide is a synthetic peptide studied in metabolic research as a dual receptor agonist: a single molecule designed to activate both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. It is a 39-amino-acid linear peptide built on the native GIP sequence and modified for enzymatic stability and albumin binding.
In this research class, tirzepatide sits between single GLP-1 receptor agonists such as semaglutide and multi-receptor compounds such as retatrutide. It has been studied extensively in published literature, including clinical research. This overview covers its structure, receptor pharmacology, research areas and laboratory handling.
This article is a scientific overview for laboratory researchers. The research-grade tirzepatide supplied by Prime Peptide Solutions is sold strictly for in-vitro laboratory research. It is not approved for human use and is not for human or animal consumption.
Background: The GIP and GLP-1 Signaling Systems
GIP signaling
GIP is an incretin hormone released by enteroendocrine K-cells of the upper small intestine in response to nutrients. It acts on the GIP receptor (GIPR), a class B G protein-coupled receptor expressed on pancreatic beta cells, in adipose tissue and in selected brain regions. Receptor activation couples to Gs proteins and raises intracellular cAMP. Native GIP is rapidly cleaved by the enzyme dipeptidyl peptidase-4 (DPP-4).
GLP-1 signaling
GLP-1, the second major incretin hormone, is secreted by intestinal L-cells. The GLP-1 receptor (GLP-1R) is also a class B G protein-coupled receptor, found on pancreatic beta cells, in the central nervous system, in the gut and in several peripheral tissues. GLP-1R signaling has been studied in connection with glucose-dependent insulin secretion, gastric emptying and appetite-related signaling pathways. Like GIP, native GLP-1 is quickly inactivated by DPP-4.
Both hormones amplify insulin secretion only when glucose is elevated, a property known as glucose dependence. Dual agonists renewed research interest in GIP receptor biology and in how the two pathways interact.
Structure and Design
The tirzepatide sequence is based on native GIP, with changes that allow it to activate the GLP-1 receptor as well. Three design features stand out:
- Aib substitutions: the non-coded amino acid alpha-aminoisobutyric acid (Aib) sits at positions 2 and 13. Aib at position 2 protects the N-terminus from DPP-4 cleavage.
- C20 fatty diacid moiety: a 20-carbon fatty diacid is attached to a lysine side chain through a hydrophilic linker. It binds reversibly to serum albumin, which slows clearance.
- C-terminal amide: the peptide ends in an amidated C-terminus rather than a free carboxylic acid.
Together, DPP-4 resistance and albumin binding give tirzepatide a half-life of about 5 days in published pharmacokinetic data, compared with a few minutes for the native hormones.
Molecule at a Glance
- Length: 39 amino acids, linear, C-terminal amide
- Molecular formula: C225H348N48O68
- Molecular weight: about 4813.5 Da
- Half-life: about 5 days (published pharmacokinetic data)
- Receptor targets: GIP receptor (GIPR) and GLP-1 receptor (GLP-1R)
Proposed Mechanism of Action
Dual receptor agonism
Binding at either GIPR or GLP-1R stimulates Gs-coupled adenylyl cyclase and raises intracellular cAMP. In pancreatic beta cells, cAMP signaling through protein kinase A and Epac2 potentiates glucose-dependent insulin secretion. Because the two receptors are co-expressed on beta cells but distributed differently in other tissues, a dual agonist lets researchers study combined incretin signaling within one molecule.
An imbalanced receptor profile
Tirzepatide is often described as an "imbalanced" agonist. In receptor-binding studies, its affinity for the GIP receptor is comparable to that of native GIP, while its affinity for the GLP-1 receptor is weaker than that of native GLP-1. The molecule therefore leans toward GIPR activity.
Biased signaling at the GLP-1 receptor
At the GLP-1 receptor, tirzepatide shows biased agonism: compared with native GLP-1, it favors cAMP generation over beta-arrestin recruitment. Beta-arrestins regulate receptor desensitization and internalization, so a ligand that recruits them less strongly can change how the receptor is trafficked at the cell surface. How this bias contributes to the overall pharmacology of the molecule remains an active research question.
How Tirzepatide Compares
Tirzepatide vs semaglutide
Semaglutide is a selective GLP-1 receptor agonist built on the GLP-1 sequence, with a C18 fatty diacid for albumin binding and a half-life of about 7 days. Tirzepatide is built on the GIP sequence, carries a C20 fatty diacid and activates GIPR as well as GLP-1R. See the semaglutide vs tirzepatide comparison for a side-by-side table, or the semaglutide research overview for its structure and mechanism.
Tirzepatide vs retatrutide
Retatrutide is also a 39-amino-acid peptide with a C20 fatty diacid, but it adds the glucagon receptor (GCGR) to GIPR and GLP-1R, and its reported half-life is about 6 days. It is reported to be more potent than native GIP at the GIP receptor and less potent than the native ligands at the GLP-1 and glucagon receptors. The tirzepatide vs retatrutide comparison sets the two side by side, and the retatrutide research overview covers the triple-agonist design.
Current Research Areas
Published work on tirzepatide in cell and animal models concentrates on a small set of pathways:
- Glucose-dependent insulin secretion: beta-cell lines and isolated islets are used to study how combined GIPR and GLP-1R activation shapes cAMP signaling and insulin release.
- Incretin receptor pharmacology: cell-based assays examine receptor binding, cAMP generation, beta-arrestin recruitment and internalization.
- Adipose tissue biology: GIPR expression in adipose tissue has prompted animal-model studies of lipid metabolism.
- Energy expenditure and hepatic metabolism: rodent models are used to examine energy balance and liver lipid metabolism under dual receptor activation.
- Gastric emptying and appetite-related signaling: both receptors are expressed in the gut and in brain regions such as the hypothalamus and brainstem.
Much of this work is comparative, with semaglutide and retatrutide serving as single- and triple-agonist references.
Stability and Laboratory Handling
General handling
Tirzepatide is supplied as a lyophilized powder and is reconstituted with bacteriostatic water (0.9% benzyl alcohol in sterile water), sold separately in 3 mL and 10 mL vials. Lyophilized vials are stored cold at 2-8 °C, or at -20 °C for long-term storage, and protected from light. The reconstituted solution is kept refrigerated at 2-8 °C, is not frozen and thawed repeatedly, and is not shaken. For vial-specific volumes, follow the tirzepatide reconstitution guide for 10mg and 20mg vials, and use the GLP-2 TZ calculator preset to work out solution concentration.
Verifying Quality
Identity and purity should be confirmed on a batch-specific Certificate of Analysis. HPLC separates the peptide from related impurities to give a purity figure, while mass spectrometry confirms identity by checking that the observed mass matches the expected molecular weight of about 4813.5 Da. Our guide on reading a peptide COA explains each field, and understanding HPLC and mass spec covers how the two methods work together.
Frequently Asked Research Questions
What makes tirzepatide a dual agonist?
It is a single peptide that activates two receptors, the GIP receptor and the GLP-1 receptor. Single agonists such as semaglutide activate the GLP-1 receptor alone, and triple agonists such as retatrutide add the glucagon receptor.
Why does tirzepatide have a long half-life?
Aib at position 2 makes the peptide resistant to DPP-4 cleavage, and the C20 fatty diacid binds serum albumin, which slows clearance.
Is tirzepatide approved for human use?
The research-grade tirzepatide sold by Prime Peptide Solutions is not approved for human use. It is supplied only as a reference material for in-vitro laboratory research and is not for human or animal consumption. The compound has been studied extensively in published literature, including clinical research, but the material in this catalog is not a medicine and should not be regarded as equivalent to any approved medicine.
How is GLP-2 TZ related to tirzepatide?
GLP-2 TZ is our catalog listing for research-grade tirzepatide. It is supplied as a lyophilized powder in 10mg and 20mg vials for in-vitro laboratory research.
What should a tirzepatide Certificate of Analysis show?
At minimum, an HPLC purity figure, a mass spectrometry identity check against the expected molecular weight, and a batch or lot number that matches the vial label.
Conclusion
Tirzepatide is a dual GIP and GLP-1 receptor agonist built on the GIP sequence, protected against DPP-4 by Aib substitutions and extended by a C20 fatty diacid that binds serum albumin. Its imbalanced receptor profile and biased signaling at the GLP-1 receptor make it a distinct tool in incretin research. For laboratories, the relevant considerations are its dual-receptor design, careful cold storage and batch-level verification by HPLC and mass spectrometry.
Disclaimer: This article is provided for educational and research purposes only. It summarizes publicly available scientific literature and does not constitute medical advice. Tirzepatide and all peptide compounds sold by Prime Peptide Solutions are intended strictly for laboratory research, are not approved for human use, and are not for human or animal consumption. Researchers are responsible for compliance with all applicable regulations in their jurisdiction.
References & Further Reading
- PubMed: Current peer-reviewed tirzepatide literature
- PubMed: Tirzepatide receptor pharmacology and biased agonism
- PubMed: Dual GIP and GLP-1 receptor agonist research
- Related: Semaglutide vs Tirzepatide: A Research Comparison
Research-Grade Tirzepatide
In our catalog, research-grade tirzepatide is listed as GLP-2 TZ (tirzepatide), supplied as a lyophilized powder in 10mg and 20mg vials. Identity and purity are documented by HPLC and mass spectrometry, and the Certificate of Analysis for every batch is published on our COA page.
Sold strictly for in-vitro laboratory research. Not for human or animal consumption.